199 related articles for article (PubMed ID: 36572751)
1. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children.
Stratmann S; Vesterlund M; Umer HM; Eshtad S; Skaftason A; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Lindskog C; Cavelier L; Lehtiö J; Holmfeldt L
Leukemia; 2023 Mar; 37(3):550-559. PubMed ID: 36572751
[TBL] [Abstract][Full Text] [Related]
2. The proteogenomic subtypes of acute myeloid leukemia.
Jayavelu AK; Wolf S; Buettner F; Alexe G; Häupl B; Comoglio F; Schneider C; Doebele C; Fuhrmann DC; Wagner S; Donato E; Andresen C; Wilke AC; Zindel A; Jahn D; Splettstoesser B; Plessmann U; Münch S; Abou-El-Ardat K; Makowka P; Acker F; Enssle JC; Cremer A; Schnütgen F; Kurrle N; Chapuy B; Löber J; Hartmann S; Wild PJ; Wittig I; Hübschmann D; Kaderali L; Cox J; Brüne B; Röllig C; Thiede C; Steffen B; Bornhäuser M; Trumpp A; Urlaub H; Stegmaier K; Serve H; Mann M; Oellerich T
Cancer Cell; 2022 Mar; 40(3):301-317.e12. PubMed ID: 35245447
[TBL] [Abstract][Full Text] [Related]
3. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
Pino JC; Posso C; Joshi SK; Nestor M; Moon J; Hansen JR; Hutchinson-Bunch C; Gritsenko MA; Weitz KK; Watanabe-Smith K; Long N; McDermott JE; Druker BJ; Liu T; Tyner JW; Agarwal A; Traer E; Piehowski PD; Tognon CE; Rodland KD; Gosline SJC
Cell Rep Med; 2024 Jan; 5(1):101359. PubMed ID: 38232702
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.
Hernandez-Valladares M; Vaudel M; Selheim F; Berven F; Bruserud Ø
Expert Rev Proteomics; 2017 Aug; 14(8):649-663. PubMed ID: 28693350
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression.
Stratmann S; Yones SA; Garbulowski M; Sun J; Skaftason A; Mayrhofer M; Norgren N; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Komorowski J; Holmfeldt L
Blood Adv; 2022 Jan; 6(1):152-164. PubMed ID: 34619772
[TBL] [Abstract][Full Text] [Related]
6. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
Stratmann S; Yones SA; Mayrhofer M; Norgren N; Skaftason A; Sun J; Smolinska K; Komorowski J; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Holmfeldt L
Blood Adv; 2021 Feb; 5(3):900-912. PubMed ID: 33560403
[TBL] [Abstract][Full Text] [Related]
7. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
Klein K; Beverloo HB; Zimmermann M; Raimondi SC; von Neuhoff C; de Haas V; van Weelderen R; Cloos J; Abrahamsson J; Bertrand Y; Dworzak M; Fynn A; Gibson B; Ha SY; Harrison CJ; Hasle H; Elitzur S; Leverger G; Maschan A; Razzouk B; Reinhardt D; Rizzari C; Smisek P; Creutzig U; Kaspers GJL
Pediatr Blood Cancer; 2022 Jan; 69(1):e29341. PubMed ID: 34532968
[TBL] [Abstract][Full Text] [Related]
9. Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.
Obszański P; Kozłowska A; Wańcowiat J; Twardowska J; Lejman M; Zawitkowska J
Molecules; 2022 Jun; 27(12):. PubMed ID: 35745032
[TBL] [Abstract][Full Text] [Related]
10. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
11. Pediatric relapsed acute myeloid leukemia: a systematic review.
Hoffman AE; Schoonmade LJ; Kaspers GJ
Expert Rev Anticancer Ther; 2021 Jan; 21(1):45-52. PubMed ID: 33111585
[No Abstract] [Full Text] [Related]
12. Individual tumor response testing in multiple relapsed acute myeloid leukemia in children.
Styczynski J; Piatkowska M; Czyzewski K; Pogorzala M; Wysocki M
Anticancer Res; 2013 Mar; 33(3):1189-93. PubMed ID: 23482801
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
14. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
16. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia.
Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM
Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222
[TBL] [Abstract][Full Text] [Related]
18. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.
Flach J; Shumilov E; Wiedemann G; Porret N; Shakhanova I; Bürki S; Legros M; Joncourt R; Pabst T; Bacher U
Hematol Oncol; 2020 Oct; 38(4):425-431. PubMed ID: 32306411
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.
Patel C; Stenke L; Varma S; Lindberg ML; Björkholm M; Sjöberg J; Viktorsson K; Lewensohn R; Landgren O; Gottesman MM; Gillet JP
Cancer; 2013 Aug; 119(16):3076-83. PubMed ID: 23674237
[TBL] [Abstract][Full Text] [Related]
20. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.
Hackl H; Astanina K; Wieser R
J Hematol Oncol; 2017 Feb; 10(1):51. PubMed ID: 28219393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
